Search for stock quotes, financial statistics and more
Research Capital analyst Andre Uddin maintained a “Buy” rating and C$5.55 price target on Medexu... Read More
Following a key product update, Raymond James analyst Michael W. Freeman remains bullish on Medexus ... Read More
An FDA approval could send one Canadian-listed stock flying, says Raymond James analysts Michael W. ... Read More
With its second quarter results in the books, Raymond James analyst Michael W. Freeman has raised it... Read More
A new development has been a drag on its share price, but Ventum Capital Markets analyst Stefan Quen... Read More
Share
Tweet
pin
Share